I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Andrew D. Dickinson net worth and biography

Andrew Dickinson Biography and Net Worth

Exec. VP & CFO of Gilead Sciences

Andrew Dickinson serves as Gilead's Chief Financial Officer, responsible for the oversight of the company’s global finance, corporate development, information technology, operations and strategy organizations.

Andy joined Gilead in 2016 and prior to his current role served as head of the company’s corporate development and strategy group. In that role, Andy drove all of Gilead’s licensing, partnership and acquisition transactions and guided investments into new areas. Prior to his tenure at Gilead, Andy was the global Co-Head of Healthcare Investment Banking at Lazard. Earlier in his career, he served as General Counsel and Vice President of Corporate Development at Myogen, Inc., which was acquired by Gilead in 2006.

Andy received his bachelor’s degree in molecular, cellular and developmental biology from the University of Colorado at Boulder and his law degree from Loyola University of Chicago.

How old is Andrew D. Dickinson?: Mr. Dickinson is currently 54 years old. There are 7 older executives and no younger executives at Gilead Sciences. The oldest executive at Gilead Sciences is Dr. Rudolf Ertl, Senior Vice President of Commercial Operations of Australia, Canada, Europe, who is 78 years old. Learn More on Andrew D. Dickinson's age.
How do I contact Andrew D. Dickinson?: The corporate mailing address for Mr. Dickinson and other Gilead Sciences executives is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. Gilead Sciences can also be reached via phone at (650) 574-3000 and via email at [email protected]. Learn More on Andrew D. Dickinson's contact information.
Has Andrew D. Dickinson been buying or selling shares of Gilead Sciences?: Andrew D. Dickinson has not been actively trading shares of Gilead Sciences during the last quarter. Learn More on Andrew D. Dickinson's trading history.
Who are Gilead Sciences' active insiders?: Gilead Sciences' insider roster includes Gregg Alton (EVP), Jeffrey Bluestone (Director), Paul Carter (EVP), John Cogan (Director), Andrew Dickinson (Exec. VP & CFO ), Andrew Dickinson (CFO), John Martin (Director), Johanna Mercier (Insider), James Meyers (EVP), John Milligan (Insider), Daniel O'Day (Chairman & CEO ), Merdad Parsey (Insider), Brett Pletcher (EVP), Javier Rodriguez (Director), Robin Washington (CFO), Richard Whitley (Director), and Diane Wilfong (CAO). Learn More on Gilead Sciences' active insiders.
Are insiders buying or selling shares of Gilead Sciences?: In the last year, insiders at the biopharmaceutical company sold shares 13 times. They sold a total of 509,823 shares worth more than $46,496,330.96. The most recent insider tranaction occured on December, 16th when CFO Andrew D Dickinson sold 8,500 shares worth more than $781,660.00. Insiders at Gilead Sciences own 0.2% of the company. Learn More about insider trades at Gilead Sciences.
Information on this page was last updated on 12/16/2024.

Andrew D. Dickinson Insider Trading History at Gilead Sciences

Andrew D. Dickinson Buying and Selling Activity at Gilead Sciences

Gilead Sciences Company Overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Today's Range

Now: $92.01

$91.72

$94.00

50 Day Range

MA: $91.51

$87.23

$97.90

2 Week Range

Now: $92.01

$62.07

$98.90

Volume

3,611,577 shs

Average Volume

7,057,779 shs

Market Capitalization

$114.67 billion

P/E Ratio

1,022.33

Dividend Yield

3.28%

Beta

0.18

I was wrong. Dead wrong.

From Porter & Company | Ad